Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares Bought by Virtu Financial LLC

Virtu Financial LLC increased its holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 180.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,157 shares of the company’s stock after acquiring an additional 24,552 shares during the quarter. Virtu Financial LLC’s holdings in Checkpoint Therapeutics were worth $122,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CKPT. PUREfi Wealth LLC acquired a new stake in shares of Checkpoint Therapeutics in the 4th quarter valued at about $32,000. SBI Securities Co. Ltd. acquired a new stake in shares of Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. Bartlett & CO. Wealth Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 375.0% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock worth $61,000 after purchasing an additional 15,000 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Checkpoint Therapeutics during the 4th quarter valued at approximately $64,000. Finally, Raymond James Financial Inc. bought a new position in Checkpoint Therapeutics during the 4th quarter worth $67,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Insider Activity

In related news, CEO James F. Oliviero III sold 9,233 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the sale, the chief executive officer now owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This trade represents a 0.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the transaction, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,674 shares of company stock valued at $336,011. Insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Price Performance

CKPT stock opened at $4.04 on Monday. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The company’s 50 day simple moving average is $3.32 and its 200-day simple moving average is $3.27. The firm has a market capitalization of $197.29 million, a P/E ratio of -2.20 and a beta of 1.41.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47). Sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Lake Street Capital reiterated a “hold” rating and set a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.